Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$86.61M-1.69%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- James C. Clemmer
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 632
- Beta
- 0.33
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 2.60
Financials
Revenue
$86.61M-1.7%Net Income
$-11.40M-977.3%EBITDA
$-28.36M-390.1%Free Cash Flow
$17.04M+144.8%EPS (diluted)
$-0.28-800.0%Shares Outstanding (diluted)
41.53M+13.2%Operating Expenses
$49.57MCash & Debt
$53.86MReturn of Capital
$0.00Revenue by Segment (annual)
$303.91MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $320.17M | $-36.74M | $-0.88 |
| 2025 | $292.50M | $-33.99M | $-0.83 |
| 2024 | $303.91M | $-184.35M | $-4.59 |
| 2023 | $338.75M | $-52.44M | $-1.33 |
| 2022 | $316.22M | $-26.55M | $-0.68 |
| 2021 | $291.01M | $-31.55M | $-0.82 |
| 2020 | $264.16M | $-166.79M | $-4.37 |
| 2019 | $359.48M | $61.34M | $1.64 |
| 2018 | $344.29M | $16.34M | $0.44 |
| 2017 | $349.64M | $-7.05M | $-0.19 |
| 2016 | $353.69M | $-43.59M | $-1.23 |
| 2015 | $356.97M | $-3.39M | $-0.09 |
| 2014 | $354.45M | $2.35M | $0.09 |
| 2013 | $342.03M | $-1.21M | $-0.02 |
Valuation
ANGOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (4)
- Newsbusinesswire.com·4d ago·Positive
…cobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Dr. Jonathan Alis, Dr. Seth I. Sokol and their team at Jacobi Hospital in Bronx, New York have been selected as an ALPHA-PE Research…
View source ↗ - Newsbusinesswire.com·7d ago·Positive
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026 LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2027 before the market open on Thursday, October 8, 2026. The Company's management will hos…
View source ↗ - Newszacks.com·53d ago·Neutral
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue? AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsmarketbeat.com·55d ago·Neutral
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027 AngioDynamics NASDAQ: ANGO expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth medical technology platforms, executives said during a Canaccord fireside chat.
View source ↗
Earnings
Thu, Oct 8(in 2 days)
Consensus estimate $-0.11 per share
Typical surprise +36.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 14$-0.07 vs $-0.11beat
- Thu, Apr 2$-0.07 vs $-0.11beat
- Tue, Jan 6$-0.15 vs $-0.10miss
- Thu, Oct 2$-0.10 vs $-0.14beat
- Tue, Jul 15$-0.03 vs $-0.13beat
- Wed, Apr 2$0.03 vs $-0.13beat
Estimates and results for ANGO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ANGO officers and directors.
- Bought
- $375k
- Sold
- $394k
7 trades
2 trades
- Nighan Warren Jrsold
- Weiss Lawrence Tbought
- Trowbridge Stephen Abought
- Clemmer James Cbought
- Nighan Warren Jrsold
- Nighan Warren Jrbought
- Trowbridge Stephen Abought
- Nighan Warren Jrbought
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Debbie Wasserman Schultzhouse · FL25 · disclosed Oct 27, 2025 (7d later)Sell$100,001 - $250,000
- Debbie Wasserman Schultzhouse · FL25 · disclosed Jul 28, 2025 (31d later)Buy$1,001 - $15,000
- Debbie Wasserman Schultzhouse · FL25 · disclosed Jul 28, 2025 (12d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.